These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 17240478

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Infliximab for the treatment of hidradenitis suppurativa.
    Fernández-Vozmediano JM, Armario-Hita JC.
    Dermatology; 2007; 215(1):41-4. PubMed ID: 17587838
    [Abstract] [Full Text] [Related]

  • 3. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa.
    Mekkes JR, Bos JD.
    Br J Dermatol; 2008 Feb; 158(2):370-4. PubMed ID: 18047504
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Etanercept: effective in the management of hidradenitis suppurativa.
    Cusack C, Buckley C.
    Br J Dermatol; 2006 Apr; 154(4):726-9. PubMed ID: 16536817
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy of infliximab for hidradenitis suppurativa: assessment of clinical and biological inflammatory markers.
    Delage M, Samimi M, Atlan M, Machet L, Lorette G, Maruani A.
    Acta Derm Venereol; 2011 Mar; 91(2):169-71. PubMed ID: 21384087
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.
    Kimball AB, Kerdel F, Adams D, Mrowietz U, Gelfand JM, Gniadecki R, Prens EP, Schlessinger J, Zouboulis CC, van der Zee HH, Rosenfeld M, Mulani P, Gu Y, Paulson S, Okun M, Jemec GB.
    Ann Intern Med; 2012 Dec 18; 157(12):846-55. PubMed ID: 23247938
    [Abstract] [Full Text] [Related]

  • 13. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.
    Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE.
    Br J Dermatol; 2006 Jun 18; 154(6):1161-8. PubMed ID: 16704649
    [Abstract] [Full Text] [Related]

  • 14. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa.
    Gulliver WP, Jemec GB, Baker KA.
    J Eur Acad Dermatol Venereol; 2012 Jul 18; 26(7):911-4. PubMed ID: 21605174
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial.
    Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA.
    J Am Acad Dermatol; 2010 Feb 18; 62(2):205-17. PubMed ID: 20115947
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of infliximab for severe recalcitrant psoriasis after 6 weeks of treatment.
    DE Oliveira JP, Levy A, Morel P, Guibal F.
    J Dermatol; 2008 Sep 18; 35(9):575-80. PubMed ID: 18837702
    [Abstract] [Full Text] [Related]

  • 20. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa.
    Leslie KS, Tripathi SV, Nguyen TV, Pauli M, Rosenblum MD.
    J Am Acad Dermatol; 2014 Feb 18; 70(2):243-51. PubMed ID: 24314876
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.